The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
Event:
ESC Acute CardioVascular Care 2022
Topic:
Pharmacotherapy
Session:
Anti-thrombotic management in patients with acute coronary syndromes (ACS)